Advancing elimination targets for viral hepatitis and HIV in Poland: estimating the cost-effectiveness of emergency department opt-out testing for blood-borne viruses
Poland continues to face challenges in meeting viral hepatitis and HIV elimination goals. Diagnosis rates for hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV remain below elimination targets, while delayed diagnosis and gaps in linkage to care contribute to poorer health outcomes. Since 2022, forced migration from Ukraine has increased the number of people Read More >
Tales from opposite corners of the world: Emergency department opt-out testing: A cost-effective route to earlier HIV and Hepatitis diagnosis in Australia and Germany
Australia and Germany have both made progress toward HIV and viral hepatitis elimination targets, yet a significant share of infections remains undiagnosed. These levels of undiagnosed infection indicate that standard blood-borne virus (BBV) testing approaches are not sufficient to meet public health goals. Emergency department opt-out testing European and US studies demonstrate the cost-effectiveness and Read More >
What are the benefits of starting biologics earlier in asthma patients? Modelling the impact of earlier initiation on outcomes and costs in the UK
Benefits of early biologics in asthma patients Read More >
When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal
In 2019, the previous UK government set the ambitious target of eliminating HIV transmission within the UK by 2030. While great progress has been made in HIV prevention and treatment in the UK, with England reaching the UNAIDS 95-95-95 target in 20231, past evidence suggested that the goal of ‘elimination’ by 2030 is unlikely to Read More >
Modelling the choice of high-risk human papillomavirus (HR-HPV) assay in the English cervical screening programme
